Nano Dimension

$Nano Dimension(NNDM)$ 8-A12B Registration of securities [Section 12(b)] Accession Number: 0001104659-26-009462  Act: 34  Size: 263 KB 网页链接

$Nano Dimension(NNDM)$ 8-K Current report, items 1.01, 3.01, 8.01, and 9.01 Accession Number: 0001104659-26-009481  Act: 34  Size: 287 KB 网页链接

$Nano Dimension(NNDM)$ 144 Report of proposed sale of securities Accession Number: 0001104659-26-019282  Act: 33  Size: 4 KB 网页链接

$Nano Dimension(NNDM)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001104659-26-005254  Act: 34  Size: 255 KB 网页链接

$Nano Dimension(NNDM)$ SCHEDULE 13D General Statement of Acquisition of Beneficial Ownership Accession Number: 0001213900-26-009570  Act: 34  Size: 39 KB 网页链接

$Nano Dimension(NNDM)$ NT 10-K Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 Accession Number: 0001104659-26-028020  Act: 34  Size: 29 KB 网页链接

$Nano Dimension(NNDM)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001193125-26-134468  Act: 34  Size: 1 MB 网页链接

$Nano Dimension(NNDM)$ 144 Report of proposed sale of securities Accession Number: 0001976408-26-000282  Act: 33  Size: 4 KB 网页链接

$Nano Dimension(NNDM)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0001193125-26-134641  Act: 34  Size: 21 MB 网页链接

$Nano Dimension(NNDM)$ 144 Report of proposed sale of securities Accession Number: 0001976408-26-000281  Act: 33  Size: 4 KB 网页链接

$Nano Dimension(NNDM)$ Oramed Pharmaceuticals Inc. 和 Nadav Kidron 联合提交了关于他们持有Nano Dimension Ltd.普通股受益所有权的Schedule 13D表格。截至2026年1月29日，Oramed Pharmaceuticals Inc. 受益持有10,413,730股，占已发行股份的5.0%。Nadav Kidron 受益持有10,549,430股，同样占已...

$Nano Dimension(NNDM)$ SCHEDULE 13D/A [Amend] General Statement of Acquisition of Beneficial Ownership Accession Number: 0001213900-26-018576  Act: 34  Size: 19 KB 网页链接